CL2014002181A1 - Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. - Google Patents
Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma.Info
- Publication number
- CL2014002181A1 CL2014002181A1 CL2014002181A CL2014002181A CL2014002181A1 CL 2014002181 A1 CL2014002181 A1 CL 2014002181A1 CL 2014002181 A CL2014002181 A CL 2014002181A CL 2014002181 A CL2014002181 A CL 2014002181A CL 2014002181 A1 CL2014002181 A1 CL 2014002181A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- crystalline form
- pyrazolopyrimidine
- lymphoma
- monohydrate
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 title 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 title 1
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 title 1
- 201000009613 breast lymphoma Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
- 150000005829 chemical entities Chemical class 0.000 title 1
- 208000029742 colonic neoplasm Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 201000005202 lung cancer Diseases 0.000 title 1
- 208000020816 lung neoplasm Diseases 0.000 title 1
- 150000004682 monohydrates Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600070P | 2012-02-17 | 2012-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002181A1 true CL2014002181A1 (es) | 2014-12-12 |
Family
ID=48982730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002181A CL2014002181A1 (es) | 2012-02-17 | 2014-08-14 | Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9290500B2 (enExample) |
| EP (3) | EP3173413B1 (enExample) |
| JP (1) | JP6122877B2 (enExample) |
| KR (1) | KR20140123104A (enExample) |
| CN (1) | CN104136399B (enExample) |
| AR (1) | AR092797A1 (enExample) |
| BR (1) | BR112014020365B1 (enExample) |
| CA (1) | CA2864672C (enExample) |
| CL (1) | CL2014002181A1 (enExample) |
| CO (1) | CO7071135A2 (enExample) |
| CR (1) | CR20140380A (enExample) |
| DO (1) | DOP2014000187A (enExample) |
| EA (1) | EA035020B1 (enExample) |
| EC (1) | ECSP14019113A (enExample) |
| ES (1) | ES2739150T3 (enExample) |
| GE (1) | GEP201706687B (enExample) |
| HK (1) | HK1201817A1 (enExample) |
| IL (1) | IL234016A0 (enExample) |
| MA (1) | MA35932B1 (enExample) |
| MX (1) | MX352963B (enExample) |
| NZ (1) | NZ628969A (enExample) |
| PE (1) | PE20142244A1 (enExample) |
| PH (1) | PH12014501832A1 (enExample) |
| SG (2) | SG10201606581RA (enExample) |
| TN (1) | TN2014000351A1 (enExample) |
| TW (1) | TWI593688B (enExample) |
| UA (1) | UA116534C2 (enExample) |
| UY (1) | UY34629A (enExample) |
| WO (1) | WO2013123169A1 (enExample) |
| ZA (1) | ZA201406103B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| EP3173413B1 (en) | 2012-02-17 | 2019-05-01 | Millennium Pharmaceuticals, Inc. | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme |
| WO2014022744A1 (en) | 2012-08-03 | 2014-02-06 | Millennium Pharmaceuticals, Inc. | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 |
| BR112015032902A8 (pt) | 2013-07-02 | 2019-12-24 | Millennium Pharm Inc | compostos de heteroarila, seus usos e composições farmacêuticas |
| EP3901159A1 (en) * | 2014-07-01 | 2021-10-27 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| TW201628621A (zh) * | 2014-10-29 | 2016-08-16 | 千禧製藥公司 | 泛素活化酶抑制劑及輻射之施用 |
| EP3212650B1 (en) | 2014-10-29 | 2021-02-17 | Millennium Pharmaceuticals, Inc. | Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents |
| MY210039A (en) | 2018-10-30 | 2025-08-22 | Kronos Bio Inc | Compounds, compositions, and methods for modulating cdk9 activity |
| CN117412973A (zh) * | 2021-05-31 | 2024-01-16 | 上海瑛派药业有限公司 | 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用 |
| WO2023021498A1 (en) * | 2021-08-16 | 2023-02-23 | Moya Bio Ltd. | Fused azole and furan based nucleoside analogs and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040023901A1 (en) | 2002-02-28 | 2004-02-05 | Cook Phillip D. | Nucleoside 5'-monophosphate mimics and their prodrugs |
| WO2004022559A1 (en) | 2002-09-04 | 2004-03-18 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN1701073B (zh) | 2002-09-04 | 2011-06-22 | 先灵公司 | 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶 |
| US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| EP1608652A1 (en) | 2003-03-31 | 2005-12-28 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| US20050130974A1 (en) | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
| JP2008503591A (ja) | 2004-06-22 | 2008-02-07 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ユビキチンリガーゼ阻害剤 |
| AU2006210422B2 (en) | 2005-02-04 | 2012-09-13 | Takeda Pharmaceutical Company Limited | Inhibitors of E1 activating enzymes |
| WO2007044426A2 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| CN106008512B (zh) | 2006-02-02 | 2019-03-12 | 千禧药品公司 | E1活化酶抑制剂 |
| JP4953472B2 (ja) * | 2006-02-28 | 2012-06-13 | ラム・リサーチ・アクチエンゲゼルシヤフト | ディスク状物品を液体処理する装置及び方法 |
| HRP20110017T1 (hr) * | 2006-08-08 | 2011-02-28 | Millennium Pharmaceuticals | Spojevi heteroarila korisni kao inhibitori e1 aktivirajućih enzima |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| JP5539864B2 (ja) | 2007-06-12 | 2014-07-02 | アカオゲン，インコーポレーテッド | 抗菌剤 |
| KR101925902B1 (ko) * | 2007-08-02 | 2018-12-06 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｅ1 활성화 효소 억제제의 합성 방법 |
| WO2009082691A1 (en) | 2007-12-21 | 2009-07-02 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| SG10201402148SA (en) * | 2009-05-14 | 2014-07-30 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| EP3064204A1 (en) | 2010-03-01 | 2016-09-07 | GTx, Inc. | Compounds for treatment of cancer |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| MX2014002015A (es) | 2011-08-24 | 2014-03-27 | Millennium Pharm Inc | Inhibidores de la enzima activadora de nedd8. |
| EP3173413B1 (en) | 2012-02-17 | 2019-05-01 | Millennium Pharmaceuticals, Inc. | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme |
| WO2014022744A1 (en) | 2012-08-03 | 2014-02-06 | Millennium Pharmaceuticals, Inc. | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 |
| BR112015032902A8 (pt) | 2013-07-02 | 2019-12-24 | Millennium Pharm Inc | compostos de heteroarila, seus usos e composições farmacêuticas |
| EP3901159A1 (en) | 2014-07-01 | 2021-10-27 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
-
2013
- 2013-02-14 EP EP16205139.5A patent/EP3173413B1/en active Active
- 2013-02-14 GE GEAP201313560A patent/GEP201706687B/en unknown
- 2013-02-14 WO PCT/US2013/026113 patent/WO2013123169A1/en not_active Ceased
- 2013-02-14 SG SG10201606581RA patent/SG10201606581RA/en unknown
- 2013-02-14 NZ NZ628969A patent/NZ628969A/en not_active IP Right Cessation
- 2013-02-14 BR BR112014020365-2A patent/BR112014020365B1/pt not_active IP Right Cessation
- 2013-02-14 CA CA2864672A patent/CA2864672C/en active Active
- 2013-02-14 US US13/767,314 patent/US9290500B2/en active Active
- 2013-02-14 CN CN201380009784.8A patent/CN104136399B/zh active Active
- 2013-02-14 SG SG11201404757WA patent/SG11201404757WA/en unknown
- 2013-02-14 JP JP2014557765A patent/JP6122877B2/ja not_active Expired - Fee Related
- 2013-02-14 MX MX2014009944A patent/MX352963B/es active IP Right Grant
- 2013-02-14 HK HK15102227.4A patent/HK1201817A1/xx unknown
- 2013-02-14 ES ES16205139T patent/ES2739150T3/es active Active
- 2013-02-14 EA EA201400831A patent/EA035020B1/ru not_active IP Right Cessation
- 2013-02-14 UA UAA201409297A patent/UA116534C2/uk unknown
- 2013-02-14 EP EP19170607.6A patent/EP3536692B1/en active Active
- 2013-02-14 PE PE2014001278A patent/PE20142244A1/es active IP Right Grant
- 2013-02-14 EP EP13748707.0A patent/EP2814791A4/en not_active Withdrawn
- 2013-02-14 KR KR1020147025556A patent/KR20140123104A/ko not_active Ceased
- 2013-02-15 AR ARP130100480A patent/AR092797A1/es unknown
- 2013-02-15 UY UY0001034629A patent/UY34629A/es not_active Application Discontinuation
- 2013-02-18 TW TW102105676A patent/TWI593688B/zh not_active IP Right Cessation
-
2014
- 2014-08-07 IL IL234016A patent/IL234016A0/en unknown
- 2014-08-11 TN TNP2014000351A patent/TN2014000351A1/fr unknown
- 2014-08-12 CR CR20140380A patent/CR20140380A/es unknown
- 2014-08-13 PH PH12014501832A patent/PH12014501832A1/en unknown
- 2014-08-14 CL CL2014002181A patent/CL2014002181A1/es unknown
- 2014-08-15 DO DO2014000187A patent/DOP2014000187A/es unknown
- 2014-08-20 ZA ZA2014/06103A patent/ZA201406103B/en unknown
- 2014-09-10 MA MA37338A patent/MA35932B1/fr unknown
- 2014-09-16 CO CO14205517A patent/CO7071135A2/es unknown
- 2014-09-17 EC ECIEPI201419113A patent/ECSP14019113A/es unknown
-
2016
- 2016-02-19 US US15/048,007 patent/US9663525B2/en active Active
-
2017
- 2017-04-17 US US15/488,800 patent/US9796725B2/en active Active
- 2017-09-08 US US15/699,818 patent/US10202389B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002181A1 (es) | Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| HK1214815A1 (zh) | Zeste增强子同源物2的抑制剂 | |
| CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
| EA201600622A1 (ru) | Бициклические анелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4 | |
| CL2015001250A1 (es) | Compuestos derivados de triazolopirazinas, inhibidores de brd4; preparacion farmaceutica; y su uso en el tratamiento y/o la prevencion de cancer, tal como cancer de pulmon, higado, colon, cerebro, tiroides, mamas, entre otros. | |
| HRP20220897T8 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| MX376008B (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| TN2015000516A1 (en) | Chemical compounds | |
| CL2012001627A1 (es) | Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer. | |
| WO2013173441A3 (en) | Enhancer of zeste homolog 2 inhibitors | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| IL231835A0 (en) | Pyrrolopyrimidine compounds for cancer treatment | |
| CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
| MA40076A (fr) | Inhibiteurs de syk | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| CL2014002386A1 (es) | Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras. | |
| CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
| CL2014000641A1 (es) | Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras. | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| EP3133073A3 (en) | Inhibitors of iap |